CA2871528A1 - Anti-pdgf-c antibodies - Google Patents

Anti-pdgf-c antibodies Download PDF

Info

Publication number
CA2871528A1
CA2871528A1 CA2871528A CA2871528A CA2871528A1 CA 2871528 A1 CA2871528 A1 CA 2871528A1 CA 2871528 A CA2871528 A CA 2871528A CA 2871528 A CA2871528 A CA 2871528A CA 2871528 A1 CA2871528 A1 CA 2871528A1
Authority
CA
Canada
Prior art keywords
antibody
seq
pdgf
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2871528A
Other languages
English (en)
French (fr)
Inventor
Claudia Fromond
Hoa Thu NGO
Richard Zwaal
Sofie NOTEBAERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxurion NV
Original Assignee
ThromboGenics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ThromboGenics NV filed Critical ThromboGenics NV
Publication of CA2871528A1 publication Critical patent/CA2871528A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2871528A 2012-04-24 2013-04-24 Anti-pdgf-c antibodies Abandoned CA2871528A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
US61/637,372 2012-04-24
EP12165314 2012-04-24
EP12165314.1 2012-04-24
US201261727231P 2012-11-16 2012-11-16
US61/727,231 2012-11-16
EP12192943.4 2012-11-16
EP12192943 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (1)

Publication Number Publication Date
CA2871528A1 true CA2871528A1 (en) 2013-10-31

Family

ID=49482233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871528A Abandoned CA2871528A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Country Status (13)

Country Link
US (1) US9884910B2 (forum.php)
EP (1) EP2841454A1 (forum.php)
JP (1) JP2015515487A (forum.php)
KR (1) KR20150005631A (forum.php)
CN (1) CN104321343A (forum.php)
AU (1) AU2013254690B2 (forum.php)
BR (1) BR112014025560A2 (forum.php)
CA (1) CA2871528A1 (forum.php)
IN (1) IN2014DN09717A (forum.php)
MX (1) MX2014012843A (forum.php)
NZ (2) NZ724395A (forum.php)
RU (1) RU2014140116A (forum.php)
WO (1) WO2013160359A1 (forum.php)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321343A (zh) 2012-04-24 2015-01-28 斯鲁姆博詹尼克斯公司 抗pdgf-c抗体
WO2017081171A1 (en) * 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
MA45493A (fr) * 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
US11352420B2 (en) 2016-07-01 2022-06-07 Paracrine Therapeutics Ab Methods and compositions for PDGF-CC inhibition
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2020005809A (es) * 2017-12-04 2020-08-20 Salvat Lab Sa Composicion topica oftalmica para tratar enfermedades del segmento posterior del ojo.
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
WO2025038442A1 (en) * 2023-08-11 2025-02-20 Invetx, Inc. Anti-il-5 antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
CN1330664A (zh) 1998-09-30 2002-01-09 路德维格癌症研究所 血小板衍生生长因子c、其编码dna及其应用
DK1137773T3 (da) * 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2001028586A1 (en) 1999-10-21 2001-04-26 Zymogenetics, Inc. Method of treating fibrosis
US7034200B2 (en) * 2000-03-28 2006-04-25 Ludwig Institute For Cancer Research Non-human transgenic animals expressing platelet-derived growth factor C (PDGF-C) and uses thereof
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20050191304A1 (en) 2003-07-25 2005-09-01 Palmer Thomas E. Method of treating hepatocellular carcinoma
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
WO2007124308A2 (en) 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CN104321343A (zh) 2012-04-24 2015-01-28 斯鲁姆博詹尼克斯公司 抗pdgf-c抗体

Also Published As

Publication number Publication date
WO2013160359A1 (en) 2013-10-31
CN104321343A (zh) 2015-01-28
MX2014012843A (es) 2017-01-23
JP2015515487A (ja) 2015-05-28
EP2841454A1 (en) 2015-03-04
RU2014140116A (ru) 2016-06-10
NZ700274A (en) 2016-10-28
US20150232546A1 (en) 2015-08-20
AU2013254690B2 (en) 2017-12-07
US9884910B2 (en) 2018-02-06
KR20150005631A (ko) 2015-01-14
BR112014025560A2 (pt) 2017-07-04
IN2014DN09717A (forum.php) 2015-07-31
AU2013254690A1 (en) 2014-11-06
NZ724395A (en) 2018-03-23

Similar Documents

Publication Publication Date Title
US9884910B2 (en) Anti-PDGF-C antibodies
TWI803637B (zh) 特異性針對gucy2c之抗體及其用途
CN103533960B (zh) c-KIT抗体及其用途
KR20190035863A (ko) 암 치료를 위한 항Siglec-7 항체
WO2014081954A1 (en) BISPECIFIC EGFR/c-Met ANTIBODIES
OA13225A (en) Anti-VEGF antibodies.
KR20100020967A (ko) 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
US20220411501A1 (en) Anti-cd117 antibodies and methods of use thereof
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
JP2020193221A (ja) 低悪性度漿液性癌におけるｈｅｒ３阻害
US20240368260A1 (en) HUMANIZED ANTI-HUMAN ßIG-H3 PROTEIN AND USES THEREOF
WO2023143444A1 (zh) 抗dkk1抗体、其药物组合物及用途
TW202308702A (zh) 使用抗BCMA抗體藥物結合物(ADC)組合γ分泌酶抑制劑(GSI)之組合療法
AU2012201667B2 (en) Anti-VEGF antibodies
WO2017015008A1 (en) Her3 antibodies
US20250296989A1 (en) ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
WO2013139956A1 (en) Antibodies abrogating cell binding to lactadherin
US20240141060A1 (en) Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
HK1185359A (en) Crystal structures of neuropilin fragments and neuropilin-antibody complexes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190424